Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,815
archived clinical trials in
Parkinsons Disease

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Clinical Research Facility
831
mi
from 43215
Tampa, FL
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
831
mi
from 43215
Tampa, FL
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Clinical Research Facility
188
mi
from 43215
Louisville, KY
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
188
mi
from 43215
Louisville, KY
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Clinical Research Facility
789
mi
from 43215
Shreveport, LA
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
789
mi
from 43215
Shreveport, LA
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Clinical Research Facility
344
mi
from 43215
Baltimore, MD
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
344
mi
from 43215
Baltimore, MD
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Clinical Research Facility
394
mi
from 43215
St Louis, MO
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
394
mi
from 43215
St Louis, MO
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Clinical Research Facility
493
mi
from 43215
Manhasset, NY
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
493
mi
from 43215
Manhasset, NY
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Clinical Research Facility
371
mi
from 43215
Raleigh, NC
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
371
mi
from 43215
Raleigh, NC
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Clinical Research Facility
590
mi
from 43215
Burlington, VT
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
590
mi
from 43215
Burlington, VT
Parkinson's Disease Isradipine Safety Study
PHASE II SAFETY AND TOLERABILITY OF ISRADIPINE (A POTENTIAL NEUROPROTECTIVE AGENT) IN PATIENTS WITH PARKINSON'S DISEASE-Stage II
Status: Archived
710 N. Lake Shore Dr.
275
mi
from 43215
Chicago, IL
Parkinson's Disease Isradipine Safety Study
PHASE II SAFETY AND TOLERABILITY OF ISRADIPINE (A POTENTIAL NEUROPROTECTIVE AGENT) IN PATIENTS WITH PARKINSON'S DISEASE-Stage II
Status: Archived
Updated: 1/1/1970
710 N. Lake Shore Dr.
275
mi
from 43215
Chicago, IL
Early Parkinson's Disease (PD) Cross-Sectional
Cross-Sectional Cohort Study of Laboratory and Clinical Patterns in Early PD
Status: Archived
University of Texas Health Science Center at Houston
990
mi
from 43215
Houston, TX
Early Parkinson's Disease (PD) Cross-Sectional
Cross-Sectional Cohort Study of Laboratory and Clinical Patterns in Early PD
Status: Archived
Updated: 1/1/1970
University of Texas Health Science Center at Houston
990
mi
from 43215
Houston, TX
Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease
Prospective Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease
Status: Archived
Philadelphia FIGHTS
416
mi
from 43215
Philadelphia, PA
Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease
Prospective Study on the Effect of External Magnetic Stimulation on Patients With Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Philadelphia FIGHTS
416
mi
from 43215
Philadelphia, PA
Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
A Phase 2 Trial of Florbetapir F18 PET Imaging of β-amyloid in Parkinson's Disease Patients With Cognitive Impairment
Status: Archived
Hospital of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
A Phase 2 Trial of Florbetapir F18 PET Imaging of β-amyloid in Parkinson's Disease Patients With Cognitive Impairment
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
University of Colorado at Denver and Health Sciences Center
1159
mi
from 43215
Denver, CO
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Updated: 1/1/1970
University of Colorado at Denver and Health Sciences Center
1159
mi
from 43215
Denver, CO
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Mile High Research Center
1161
mi
from 43215
Denver, CO
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Updated: 1/1/1970
Mile High Research Center
1161
mi
from 43215
Denver, CO
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
CNI Movement Disorders Center
1163
mi
from 43215
Englewood, CO
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Updated: 1/1/1970
CNI Movement Disorders Center
1163
mi
from 43215
Englewood, CO
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Suncoast Neuroscience Associates, Inc
841
mi
from 43215
St. Petersburg, FL
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Updated: 1/1/1970
Suncoast Neuroscience Associates, Inc
841
mi
from 43215
St. Petersburg, FL
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Univeristy of South Florida
822
mi
from 43215
Tampa, FL
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Updated: 1/1/1970
Univeristy of South Florida
822
mi
from 43215
Tampa, FL
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Detroit Clinical Research Center
174
mi
from 43215
Novi, MI
Study of the Application of Magnetic Fields for the Treatment of Parkinson's Disease
A Randomized, Double-Blind, Sham-Stimulation Controlled Study of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Parkinson's Disease: Phase Three Clinical Trial Protocol
Status: Archived
Updated: 1/1/1970
Detroit Clinical Research Center
174
mi
from 43215
Novi, MI
Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease
Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease
Status: Archived
Atlanta VA Medical Center
430
mi
from 43215
Decatur, GA
Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease
Behavioral Therapy to Treat Urinary Incontinence in Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Atlanta VA Medical Center
430
mi
from 43215
Decatur, GA
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Parkinson Institute
2099
mi
from 43215
Sunnyvale, CA
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Parkinson Institute
2099
mi
from 43215
Sunnyvale, CA
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
The Institute for Neurodegenerative Disorders
537
mi
from 43215
New Haven, CT
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
The Institute for Neurodegenerative Disorders
537
mi
from 43215
New Haven, CT
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Mayo Clinic - Jacksonville, Florida
676
mi
from 43215
Jacksonville, FL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Mayo Clinic - Jacksonville, Florida
676
mi
from 43215
Jacksonville, FL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
University of Miami Hospital
993
mi
from 43215
Miami, FL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
University of Miami Hospital
993
mi
from 43215
Miami, FL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
University of South Flordia
831
mi
from 43215
Tampa, FL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
University of South Flordia
831
mi
from 43215
Tampa, FL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Emory Umiversity School of Medicine
432
mi
from 43215
Atlanta, GA
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Emory Umiversity School of Medicine
432
mi
from 43215
Atlanta, GA
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Pacific Health Institute
4500
mi
from 43215
Honolulu, HI
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Pacific Health Institute
4500
mi
from 43215
Honolulu, HI
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Northwestern University
274
mi
from 43215
Chicago, IL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Northwestern University
274
mi
from 43215
Chicago, IL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Rush University Medical Center
277
mi
from 43215
Chicago, IL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Rush University Medical Center
277
mi
from 43215
Chicago, IL
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Boston Med Center
643
mi
from 43215
Boston, MA
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Boston Med Center
643
mi
from 43215
Boston, MA
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Michigan State University
205
mi
from 43215
East Lansing, MI
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Michigan State University
205
mi
from 43215
East Lansing, MI
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Park Nicolet Clinic
631
mi
from 43215
Golden Valley, MN
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Park Nicolet Clinic
631
mi
from 43215
Golden Valley, MN
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
University of Minnesota Medical Center
624
mi
from 43215
Minneapolis, MN
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
University of Minnesota Medical Center
624
mi
from 43215
Minneapolis, MN
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Washington University
397
mi
from 43215
St. Louis, MO
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Washington University
397
mi
from 43215
St. Louis, MO
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Strong Memorial Hospital (University of Rochester School of Medicine)
358
mi
from 43215
Rochester, NY
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
Strong Memorial Hospital (University of Rochester School of Medicine)
358
mi
from 43215
Rochester, NY
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
University of Cincinnati Medical Center
97
mi
from 43215
Cincinnati, OH
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
University of Cincinnati Medical Center
97
mi
from 43215
Cincinnati, OH
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
University of Pittsburgh
164
mi
from 43215
Pittsburgh, PA
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
University of Pittsburgh
164
mi
from 43215
Pittsburgh, PA
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
University of Tennessee
508
mi
from 43215
Memphis, TN
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease
Status: Archived
Updated: 1/1/1970
University of Tennessee
508
mi
from 43215
Memphis, TN
The Effects of Treadmill Versus Agility Training in Parkinson's Disease
Status: Archived
Oregon Health and Science University
2026
mi
from 43215
Portland, OR
The Effects of Treadmill Versus Agility Training in Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Oregon Health and Science University
2026
mi
from 43215
Portland, OR
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
University of Alabama at Birmingham
493
mi
from 43215
Birmingham, AL
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
University of Alabama at Birmingham
493
mi
from 43215
Birmingham, AL
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Veterans Affairs Medical Center - New York
478
mi
from 43215
New York, NY
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Veterans Affairs Medical Center - New York
478
mi
from 43215
New York, NY
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Unversity of California, San Francisco
2108
mi
from 43215
San Francisco, CA
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Unversity of California, San Francisco
2108
mi
from 43215
San Francisco, CA
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Emory University
435
mi
from 43215
Atlanta, GA
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Emory University
435
mi
from 43215
Atlanta, GA
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Rush University Medical Center
277
mi
from 43215
Chicago, IL
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Rush University Medical Center
277
mi
from 43215
Chicago, IL
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
480
mi
from 43215
New York, NY
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Columbia Presbyterian Med Ctr
481
mi
from 43215
New York, NY
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
481
mi
from 43215
New York, NY
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Beth Israel Deaconess Medical Center
643
mi
from 43215
Boston, MA
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
643
mi
from 43215
Boston, MA
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Hospital of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
414
mi
from 43215
Philadelphia, PA
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Baylor School of Medicine
995
mi
from 43215
Houston, TX
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1/2 Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects With Idiopathic Parkinson's Disease
Status: Archived
Updated: 1/1/1970
Baylor School of Medicine
995
mi
from 43215
Houston, TX